journal article·2015-07-28Open access

Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes

Anders E. Hansen, Anncatrine L. Petersen, Jonas R. Henriksen, Betina Boerresen, Palle Rasmussen, Dennis R. Elema, Per Munck af Rosenschöld, Annemarie T. Kristensen, Andreas Kjær, Thomas L. Andresen

ACS Nano· Volume 9· Issue 7

Abstract

Since the first report of the enhanced permeability and retention (EPR) effect, the research in nanocarrier based antitumor drugs has been intense. The field has been devoted to treatment of cancer by exploiting EPR-based accumulation of nanocarriers in solid tumors, which for many years was considered to be a ubiquitous phenomenon. However, the understanding of differences in the EPR-effect between tumor types, heterogeneities within each patient group, and dependency on tumor development stage in humans is sparse. It is therefore important to enhance our understanding of the EPR-effect in large animals and humans with spontaneously developed cancer. In the present paper, we describe a novel loading method of copper-64 into PEGylated liposomes and use these liposomes to evaluate the EPR-effect in 11 canine cancer patients with spontaneous solid tumors by PET/CT imaging. We thereby provide the first high-resolution analysis of EPR-based tumor accumulation in large animals. We find that the EPR-effect is strong in some tumor types but cannot be considered a general feature of solid malignant tumors since we observed a high degree of accumulation heterogeneity between tumors. Six of seven included carcinomas displayed high uptake levels of liposomes, whereas one of four sarcomas displayed signs of liposome retention. We conclude that nanocarrier-radiotracers could be important in identifying cancer patients that will benefit from nanocarrier-based therapeutics in clinical practice.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Nanomedicine and Theranostics, DTU Nanotech, Technical University of Denmark, Building 423, DK-2800 Lyngby, Denmark

Department of Clinical Physiology, Nuclear Medicine & PET, and Cluster for Molecular Imaging, Rigshospitalet, Copenhagen University Hospital and Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark

DTU Chemistry, Technical University of Denmark, Building 206, DK-2800 Lyngby, Denmark

Department of Veterinary Clinical and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Dyrlaegevej 16, DK-1870 Frederiksberg, Denmark

DTU Nutech, Hevesy Laboratory, Technical University of Denmark, Frederiksborgvej 399, DK-4000 Roskilde, Denmark

Radiation Medicine Research Center, Department of Radiation Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Funding

Strategisk Forskningsrad · European Research Council · Lundbeckfonden

References (33)

Show source-provided references
1. Barenholz Y. · J. Controlled Release · 2012 · 160 · 11710.1016/j.jconrel.2012.03.020 ↗
2. Hrkach J. · Sci. Transl. Med. · 2012 · 4 · 128ra3910.1126/scitranslmed.3003651 ↗
3. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
4. Bangham A. D. · BioEssays · 1995 · 17 · 108110.1002/bies.950171213 ↗
5. Iyer A. K. · Drug Discovery Today · 2006 · 11 · 81210.1016/j.drudis.2006.07.005 ↗
6. Zhang L. · Clin. Pharm. Ther. · 2008 · 83 · 76110.1038/sj.clpt.6100400 ↗
7. Folkman J. · Curr. Mol. Med. · 2003 · 3 · 64310.2174/1566524033479465 ↗
8. Hanahan D. · Cell · 2011 · 144 · 64610.1016/j.cell.2011.02.013 ↗
9. Maeda H. · Eur. J. Pharm. Biopharm. · 2009 · 71 · 40910.1016/j.ejpb.2008.11.010 ↗
10. Fang J. · Adv. Drug Delivery Rev. · 2011 · 63 · 13610.1016/j.addr.2010.04.009 ↗
11. Denison T. A. · J. Controlled Release · 2012 · 164 · 18710.1016/j.jconrel.2012.04.014 ↗
12. Connolly D. T. · J. Clin. Invest. · 1989 · 84 · 147010.1172/JCI114322 ↗
13. Minko T. · Pharm. Res. · 2000 · 17 · 50510.1023/A:1007500412442 ↗
14. Safra T. · Oncologist · 2003 · 8 · 1710.1634/theoncologist.8-suppl_2-17 ↗
15. Harrington K. J. · Clin. Cancer Res. · 2001 · 7 · 243
16. Presant C. A. · Lancet · 1990 · 335 · 130710.1016/0140-6736(90)91188-G ↗
17. Khalifa A. · Nucl. Med. Commun. · 1997 · 18 · 1710.1097/00006231-199701000-00005 ↗
18. Presant C. A. · Cancer · 1988 · 62 · 90510.1002/1097-0142(19880901)62:5<905::AID-CNCR2820620509>3.0.CO;2-3 ↗
19. Paoloni M. · Nat. Rev. Cancer · 2008 · 8 · 14710.1038/nrc2273 ↗
20. Gambhir S. S. · Nat. Rev. Cancer · 2002 · 2 · 68310.1038/nrc882 ↗
21. Phelps M. E. · J. Nucl. Med. · 1975 · 16 · 210
22. Seo J. W. · J. Controlled Release · 2011 · 151 · 2810.1016/j.jconrel.2011.01.008 ↗
23. Willmann J. K. · Nat. Rev. Drug Discovery · 2008 · 7 · 59110.1038/nrd2290 ↗
24. Petersen A. L. · Biomaterials · 2011 · 32 · 233410.1016/j.biomaterials.2010.11.059 ↗
25. Hansen A. E. · Vet. Radiol. Ultrasound · 2011 · 52 · 20110.1111/j.1740-8261.2010.01757.x ↗
26. Phillips W. T. · Adv. Drug Delivery Rev. · 1999 · 37 · 1310.1016/S0169-409X(98)00108-2 ↗
27. Gabizon A. · Clin. Pharmacokinet. · 2003 · 42 · 41910.2165/00003088-200342050-00002 ↗
28. Gabizon A. A. · Clin. Cancer Res. · 2001 · 7 · 223
29. Harrington K. J. · Br. J. Cancer · 2000 · 83 · 68410.1054/bjoc.2000.1320 ↗
30. Petersen A. L. · J. Controlled Release · 2012 · 160 · 25410.1016/j.jconrel.2011.12.038 ↗
31. Cheng C. J. · Nat. Nanotechnol. · 2012 · 7 · 34610.1038/nnano.2012.89 ↗
32. Manzoor A. A. · Cancer Res. · 2012 · 72 · 556610.1158/0008-5472.CAN-12-1683 ↗
33. Gillies R. J. · Nat. Rev. Cancer · 2012 · 12 · 48710.1038/nrc3298 ↗